AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20574018 — intervention group
Group type: COMPARATOR
Intervention: Fellow eyes (control group)
Number of subjects: 10
Study 18056100 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Widman flap (MWF)
Number of subjects: 56
Study 18056100 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap with osseous resection (OF)
Number of subjects: 56
Study 18056100 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingivectomy (GV)
Number of subjects: 56
Study 18056100 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 56
Study 18056100 — intervention group
Group type: EXPERIMENTAL
Intervention: All surgical procedures
Number of subjects: 56
Study 18056100 — intervention group
Group type: EXPERIMENTAL
Intervention: All therapies
Number of subjects: 56
Study 16129715 — intervention group
Group type: EXPERIMENTAL
Intervention: Forskolin (250 mg of 10% forskolin extract twice a day)
Number of subjects: 30
Study 16129715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12405362 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g IV as soon as SAH diagnosis was verified, followed by 1 g every 6 hours until aneurysm occlusion, not exceeding 72 hours)
Number of subjects: 505
Study 12405362 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tranexamic acid treatment)
Number of subjects: 505
Study 10091409 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc99m‐sestaMIBI scintigraphy
Number of subjects: 55
Study 10091409 — intervention group
Group type: COMPARATOR
Intervention: Conventional Xr
Number of subjects: 55
Study 7771608 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulant therapy
Number of subjects: 50
Study 7771608 — intervention group
Group type: EXPERIMENTAL
Intervention: Monospecific antivenom (AVS)
Number of subjects: 50
Study 7771608 — intervention group
Group type: COMPARATOR
Intervention: No treatment with AVS
Number of subjects: 50
Study 2124756 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil, 10 mg in 5 minutes (n = 29)
Number of subjects: 69
Study 2124756 — intervention group
Group type: EXPERIMENTAL
Intervention: flecainide, 2 mg/kg in 10 minutes (n = 20)
Number of subjects: 69
Study 2124756 — intervention group
Group type: EXPERIMENTAL
Intervention: propafenone, 2 mg/kg in 10 minutes (n = 20)
Number of subjects: 69
Study 463537 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour by amniotomy and intravenous oxytocin infusion
Number of subjects: 80
Study 463537 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous labour followed by amniotomy (Control)
Number of subjects: 80
Study 463537 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Induction and Control)
Number of subjects: 80
Study 31346896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative GCPC risk score based on demographic/tumor characteristics
Number of subjects: 4285
Study 30055127 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg daily)
Number of subjects: 120
Study 30055127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 28499363 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated foot orthoses (n = 47)
Number of subjects: 88
Study 28499363 — intervention group
Group type: COMPARATOR
Intervention: Rocker‐sole footwear (n = 41)
Number of subjects: 88
Study 25623736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation plus standard treatment
Number of subjects: 126
Study 25623736 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 126
Study 22542709 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 280
Study 22542709 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 280
Study 20638813 — intervention group
Group type: EXPERIMENTAL
Intervention: Message emphasizing the value of patient-centeredness
Number of subjects: 384
Study 20638813 — intervention group
Group type: COMPARATOR
Intervention: Neutral message
Number of subjects: 384
Study 20638813 — intervention group
Group type: COMPARATOR
Intervention: Message emphasizing technical competence
Number of subjects: 384
Study 18401974 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravaginal dose of Polyhexamethylene Biguanide (PHMB)
Number of subjects: 740
Study 18401974 — intervention group
Group type: COMPARATOR
Intervention: Seven daily doses of Clindamycin vaginal cream
Number of subjects: 740
Study 18401974 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravaginal dose of Polyhexamethylene Biguanidine (PHMB)
Number of subjects: 740
Study 16326006 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygotes of minor alleles in SNP8NRG241930
Number of subjects: 0
Study 16326006 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygotes of minor alleles in SNP8NRG243177
Number of subjects: 0
Study 16326006 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygotes of minor alleles in rs1081062
Number of subjects: 0
Study 16326006 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype constructed from four SNPs
Number of subjects: 0
Study 14687261 — intervention group
Group type: EXPERIMENTAL
Intervention: Active learning curriculum using standardized patients
Number of subjects: 0
Study 14687261 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11198264 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ascorbic acid
Number of subjects: 20
Study 11198264 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg ascorbic acid
Number of subjects: 20
Study 11198264 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 mg ascorbic acid
Number of subjects: 20
Study 11198264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11198264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (all doses)
Number of subjects: 20
Study 9160496 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment among compliers
Number of subjects: 0
Study 9160496 — intervention group
Group type: COMPARATOR
Intervention: Intent-to-treat analysis
Number of subjects: 0
Study 8416762 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5‐10 mg once daily
Number of subjects: 80
Study 8416762 — intervention group
Group type: COMPARATOR
Intervention: Nadolol 40‐160 mg once daily
Number of subjects: 80
Study 3091718 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucin-containing saliva substitute
Number of subjects: 42
Study 3091718 — intervention group
Group type: COMPARATOR
Intervention: CMC-containing saliva substitute
Number of subjects: 42
Study 29657205 — intervention group
Group type: EXPERIMENTAL
Intervention: Xyla-P cream
Number of subjects: 0
Study 29657205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold compress
Number of subjects: 0
Study 29657205 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 27002783 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdose Education (OE) intervention (small group lecture, slideshow, and handout)
Number of subjects: 43
Study 27002783 — intervention group
Group type: COMPARATOR
Intervention: Historical non-intervention control group
Number of subjects: 43
Study 25565669 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 38
Study 25565669 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited Sampling Strategies (LSS)
Number of subjects: 38
Study 25565669 — intervention group
Group type: COMPARATOR
Intervention: Validation group
Number of subjects: 38
Study 23559222 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg oral yohimbine
Number of subjects: 23
Study 23559222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 20213026 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin ultrasonic tip
Number of subjects: 15
Study 20213026 — intervention group
Group type: COMPARATOR
Intervention: Traditional tip
Number of subjects: 15
Study 20213026 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study 19134065 — intervention group
Group type: EXPERIMENTAL
Intervention: V.A.C. therapy
Number of subjects: 10
Study 19134065 — intervention group
Group type: COMPARATOR
Intervention: Redon bottles
Number of subjects: 10
Study 15901043 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg twice daily, n = 7)
Number of subjects: 20
Study 15901043 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (12.5 mg once daily for two days and thereafter 25 mg daily, n = 7)
Number of subjects: 20
Study 15901043 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg once daily, n = 6)
Number of subjects: 20
Study 15901043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12687534 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg daily by subcutaneous injection)
Number of subjects: 1414
Study 12687534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1414
Study 10797162 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hospital discharge and home‐based rehabilitation
Number of subjects: 86
Study 10797162 — intervention group
Group type: COMPARATOR
Intervention: Conventional in‐hospital rehabilitation and community care
Number of subjects: 86
Study 8635937 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine 250 mg, two capsules twice daily
Number of subjects: 58
Study 8635937 — intervention group
Group type: COMPARATOR
Intervention: Placebo, two capsules twice daily
Number of subjects: 58
Study 1615937 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis with absolute alcohol (group 1)
Number of subjects: 39
Study 1615937 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (blood transfusions, antacids, and ranitidine) (group 2)
Number of subjects: 39
Study 6435856 — intervention group
Group type: EXPERIMENTAL
Intervention: LMS (+) regimen
Number of subjects: 0
Study 6435856 — intervention group
Group type: COMPARATOR
Intervention: LMS (−) regimen
Number of subjects: 0
Study 6435856 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LMS (+) and LMS (−))
Number of subjects: 0
Study 29950147 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-life care provided by assistant nurses
Number of subjects: 7
Study 29950147 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience-based knowledge in end-of-life care
Number of subjects: 7
Study 29950147 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentive end-of-life care focusing on bodily care
Number of subjects: 7
Study 29950147 — intervention group
Group type: EXPERIMENTAL
Intervention: Support and education for assistant nurses
Number of subjects: 7
Study 29950147 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational support for care
Number of subjects: 7
Study 28548556 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified physical education unit (mountain biking)
Number of subjects: 300
Study 28548556 — intervention group
Group type: COMPARATOR
Intervention: Standard physical education
Number of subjects: 300
Study 28548556 — intervention group
Group type: COMPARATOR
Intervention: No physical education
Number of subjects: 300
Study 27507807 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case management and outreach notifications for STIs at 1 and 3 months
Number of subjects: 153
Study 25316469 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular intermittent bolus (RIB) - 10 ml of 0.08% ropivacaine + 0.4 ug·ml‐1 sufentanil administered once an hour
Number of subjects: 132
Study 25316469 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (CI) - same solution continuously infused at a rate of 10 ml·h‐1
Number of subjects: 132
Study 22972817 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 434
Study 22972817 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 434
Study 22972817 — intervention group
Group type: EXPERIMENTAL
Intervention: hVISA strains (14.5%)
Number of subjects: 434
Study 22972817 — intervention group
Group type: EXPERIMENTAL
Intervention: CC5
Number of subjects: 434
Study 22972817 — intervention group
Group type: EXPERIMENTAL
Intervention: CC8
Number of subjects: 434
Study 22972817 — intervention group
Group type: EXPERIMENTAL
Intervention: CC239
Number of subjects: 434
Study 22972817 — intervention group
Group type: EXPERIMENTAL
Intervention: USA300
Number of subjects: 434
Study 22972817 — intervention group
Group type: EXPERIMENTAL
Intervention: hVISA prevalence
Number of subjects: 434
Study 19362290 — intervention group
Group type: EXPERIMENTAL
Intervention: V-Y advancement flap (VYAF)
Number of subjects: 238
Study 19362290 — intervention group
Group type: COMPARATOR
Intervention: Simple primary closure (AL group)
Number of subjects: 238
Study 19362290 — intervention group
Group type: COMPARATOR
Intervention: Simple primary closure (SS group)
Number of subjects: 238
Study 19362290 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 238
Study 17278988 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (VAL)
Number of subjects: 659
Study 17278988 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (AML)
Number of subjects: 659
Study 17278988 — intervention group
Group type: COMPARATOR
Intervention: Combined cardiovascular endpoints
Number of subjects: 659
Study 15643212 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy (PCNL)
Number of subjects: 79
Study 15643212 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 79
Study 11863247 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced alcohol period
Number of subjects: 33
Study 11863247 — intervention group
Group type: COMPARATOR
Intervention: Usual alcohol period
Number of subjects: 33
Study 10410207 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (diaphragm breathing with incentive spirometry and postural drainage)
Number of subjects: 27
Study 10410207 — intervention group
Group type: COMPARATOR
Intervention: Treatment B (diaphragm breathing with positive expiratory pressure (PEP-mask) and postural drainage)
Number of subjects: 27
Study 10410207 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 27
Study 10410207 — intervention group
Group type: COMPARATOR
Intervention: Treatment B
Number of subjects: 27
Study 10410207 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 27
Study 7774781 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal parenting communication classes (two second-trimester classes)
Number of subjects: 70
Study 7774781 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 1566987 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of resistance to saline technique
Number of subjects: 0
Study 1566987 — intervention group
Group type: COMPARATOR
Intervention: Paraesthesia technique
Number of subjects: 0
Study 4014868 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 6
Study 4014868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30797673 — intervention group
Group type: EXPERIMENTAL
Intervention: External cold and vibration
Number of subjects: 0
Study 30797673 — intervention group
Group type: EXPERIMENTAL
Intervention: Blowing soap bubbles
Number of subjects: 0
Study 30797673 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30077350 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg intravenous ibuprofen in 100 mL saline solution
Number of subjects: 50
Study 30077350 — intervention group
Group type: COMPARATOR
Intervention: 100 mL intravenous saline solution
Number of subjects: 50
Study 28007113 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID (bromfenac 0.1% [Bronuck])
Number of subjects: 59
Study 28007113 — intervention group
Group type: COMPARATOR
Intervention: Steroid (prednisolone acetate 1.0% [Pred Forte])
Number of subjects: 59
Study 24491639 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% glucose eye drops
Number of subjects: 29
Study 24491639 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline eye drops
Number of subjects: 29
Study 22143717 — intervention group
Group type: EXPERIMENTAL
Intervention: AH 26 + gutta‐percha
Number of subjects: 80
Study 22143717 — intervention group
Group type: EXPERIMENTAL
Intervention: AH 26 + BeeFill
Number of subjects: 80
Study 22143717 — intervention group
Group type: EXPERIMENTAL
Intervention: AH 26 + Thermafil
Number of subjects: 80
Study 22143717 — intervention group
Group type: COMPARATOR
Intervention: Instrumentation (no filling)
Number of subjects: 80
Study 22143717 — intervention group
Group type: COMPARATOR
Intervention: Non-prepared group
Number of subjects: 80
Study 20382089 — intervention group
Group type: EXPERIMENTAL
Intervention: FTW learner‐centered fruit and vegetable class
Number of subjects: 60
Study 20382089 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no specific intervention mentioned)
Number of subjects: 60
Study 18407313 — intervention group
Group type: EXPERIMENTAL
Intervention: Random jittering of orthogonal property (width, aspect ratio, area)
Number of subjects: 0
Study 18407313 — intervention group
Group type: COMPARATOR
Intervention: Unjittered trials
Number of subjects: 0
Study 15816575 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil TCI with initial effect site concentration of 1.5 ng mL(‐1)
Number of subjects: 44
Study 15816575 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl TCI with initial effect site concentration of 2 ng mL(‐1)
Number of subjects: 44
Study 11952049 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy to one randomly selected orbit
Number of subjects: 42
Study 11952049 — intervention group
Group type: COMPARATOR
Intervention: Sham radiotherapy to the other side
Number of subjects: 42
Study 9771182 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms (0.3 ml) fentanyl added to 2.5 ml 0.5% hyperbaric bupivacaine
Number of subjects: 40
Study 9771182 — intervention group
Group type: COMPARATOR
Intervention: 0.3 ml 0.9% saline (control group)
Number of subjects: 40
Study 7930890 — intervention group
Group type: EXPERIMENTAL
Intervention: Telfa
Number of subjects: 0
Study 7930890 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraffin gauze
Number of subjects: 0
Study 7930890 — intervention group
Group type: COMPARATOR
Intervention: BIPP
Number of subjects: 0
Study 7930890 — intervention group
Group type: COMPARATOR
Intervention: Merocel
Number of subjects: 0
Study 2979003 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine hydrochloride 2.5% and 10% for muscle stimulation
Number of subjects: 10
Study 2979003 — intervention group
Group type: COMPARATOR
Intervention: Guanethidine 5% and thymoxamine hydrochloride 0.5% for muscle inhibition
Number of subjects: 10
Study 31912391 — intervention group
Group type: EXPERIMENTAL
Intervention: Soil profiles under trees (site 2 and 5)
Number of subjects: 6
Study 31912391 — intervention group
Group type: COMPARATOR
Intervention: Open field (sites 1, 3, 4 and 6)
Number of subjects: 6
Study 31912391 — intervention group
Group type: EXPERIMENTAL
Intervention: Top soil layers
Number of subjects: 6
Study 31912391 — intervention group
Group type: EXPERIMENTAL
Intervention: Soil profiles under trees
Number of subjects: 6
Study 29482525 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based grief therapy
Number of subjects: 0
Study 29482525 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 27562481 — intervention group
Group type: EXPERIMENTAL
Intervention: High-egg diet (> 4 eggs per week)
Number of subjects: 0
Study 27562481 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-egg diet (1-3 eggs per week)
Number of subjects: 0
Study 27562481 — intervention group
Group type: COMPARATOR
Intervention: Egg-free diet
Number of subjects: 0
Study 27562481 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal egg ingestion
Number of subjects: 0
Study 24713286 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound whole grain-soybean
Number of subjects: 163
Study 24713286 — intervention group
Group type: COMPARATOR
Intervention: Health education (Control)
Number of subjects: 163
Study 24071752 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program consisting of five sessions
Number of subjects: 58
Study 24071752 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 58
Study 20575206 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond XT
Number of subjects: 140
Study 20575206 — intervention group
Group type: EXPERIMENTAL
Intervention: Blūgloo
Number of subjects: 140
Study 20575206 — intervention group
Group type: EXPERIMENTAL
Intervention: BeautyOrtho Bond
Number of subjects: 140
Study 20575206 — intervention group
Group type: EXPERIMENTAL
Intervention: Enlight
Number of subjects: 140
Study 20575206 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Bond
Number of subjects: 140
Study 20575206 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond CC
Number of subjects: 140
Study 20575206 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno Ortho
Number of subjects: 140
Study 16936646 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005%
Number of subjects: 34
Study 16936646 — intervention group
Group type: EXPERIMENTAL
Intervention: travoprost 0.004%
Number of subjects: 34
Study 16936646 — intervention group
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Number of subjects: 34
Study 16936646 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 34
Study 17012900 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine plus SRL 172
Number of subjects: 58
Study 17012900 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine plus placebo
Number of subjects: 58
Study 14555586 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory relaxation feedback (RFB) during CO(2) rebreathing
Number of subjects: 24
Study 14555586 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) trial session and CO(2) RFB session
Number of subjects: 24
Study 14555586 — intervention group
Group type: COMPARATOR
Intervention: CO(2) trial session and CO(2) no-feedback (NFB) session
Number of subjects: 24
Study 10757582 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive epidural anaesthesia (HEA)
Number of subjects: 30
Study 10757582 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia (SPA)
Number of subjects: 30